The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.
 
Huiyan Luo
No Relationships to Disclose
 
Jin Lu
No Relationships to Disclose
 
Yuxian Bai
No Relationships to Disclose
 
Teng Mao
No Relationships to Disclose
 
Jun Wang
No Relationships to Disclose
 
Qingxia Fan
No Relationships to Disclose
 
Yiping Zhang
No Relationships to Disclose
 
Kuaile Zhao
No Relationships to Disclose
 
Zhendong Chen
No Relationships to Disclose
 
Shegan Gao
No Relationships to Disclose
 
Jiancheng Li
No Relationships to Disclose
 
Zhichao Fu
No Relationships to Disclose
 
Kangsheng Gu
No Relationships to Disclose
 
Zhihua Liu
No Relationships to Disclose
 
Lin Wu
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Hengrui Medicine; Innovate Biopharmaceuticals; Lilly; MSD; Pfizer; Roche China
 
Xiaodong Zhang
No Relationships to Disclose
 
Jifeng Feng
No Relationships to Disclose
 
Zhen Sheng
Employment - Jiangsu Hengrui Medicine
 
Wanqin Zeng
Employment - Jiangsu Hengrui Medicine
 
Rui-Hua Xu
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; CPPC; Hengrui Pharm; Hutchison MediPharma; Innovent Biologics; Junshi Pharmaceuticals; Keymed Biosience; Merck Serono; MSD; QiLu Pharmaceutical; Roche